We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alector Inc | NASDAQ:ALEC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.34 | 5.34 | 5.35 | 5.68 | 5.325 | 5.46 | 123,620 | 18:23:27 |
“During the third quarter, Alector reached a significant inflection point, validating our immuno-neurology approach and advancing our lead programs as we strive to help patients with neurodegenerative diseases,” said Arnon Rosenthal, Ph.D., co-founder and Chief Executive Officer of Alector. “We reported 12-month Phase 2 data for our lead therapeutic candidate, AL001, in which progranulin levels in frontotemporal dementia patients reverted to normal, and for the first time, showed encouraging early evidence of a slowing of disease progression across diverse datapoints. The signing of a collaborative agreement with GSK will further enable us to develop our progranulin franchise programs to their full potential in frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease. These achievements, alongside steady progress across our portfolio, are moving us ever closer to realizing our mission of harnessing the innate immune system to halt the destruction of neurodegenerative diseases.”
Clinical Updates
Progranulin Franchise
Alzheimer’s Disease Portfolio
Corporate News
Third Quarter 2021 Financial Results
Revenue. Collaboration revenue for the quarter ended September 30, 2021, was $182.4 million, compared to $5.9 million for the same period in 2020. In August, Alector received $500 million as part of the collaboration agreement with GSK. The increase in 2021 third quarter revenue was mainly due to the recognition of $179.8 million of the upfront payment from GSK.
R&D Expenses. Total research and development expenses for the quarter ended September 30, 2021, were $43.1 million, compared to $43.8 million for the quarter ended September 30, 2020. The decrease in R&D expenses was attributable to timing of manufacturing of drug supply and clinical trials start-up costs.
G&A Expenses. Total general and administrative expenses for the quarter ended September 30, 2021, were $13.0 million, compared to $15.8 million for the same period in 2020. This decrease was primarily due to reduced legal fees.
Net Income (Loss). For the quarter ended September 30, 2021, Alector reported a net income of $126.6 million, or $1.56 net income per share, compared to a net loss of $52.7 million, or $0.67 net loss per share, for the same period in 2020.
Cash Position. Cash, cash equivalents, and marketable securities were $777.9 million as of September 30, 2021.
About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
(1) Paul, Robert, et al, “AAIC 2021 “Twelve month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 in Frontotemporal Dementia Patients with a Progranulin Mutation (FTD-GRN)”(2) Guerreiro, et al. “TREM2 Variants in Alzheimer’s Disease” NEJM. 2013; and Jonsson, et al. “Variant of TREM2 associated with the risk of Alzheimer's disease” NEJM 2013
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions, Alector and its business as set forth in our Quarterly Report on Form 10-Q, as filed on November 4, 2021 with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Selected Consolidated Balance Sheet Data(in thousands)
September 30, | December 31, | |||||
2021 | 2020 | |||||
Cash, cash equivalents, and marketable securities | $ | 777,850 | $ | 413,308 | ||
Total assets | 854,226 | 488,251 | ||||
Total current liabilities (excluding deferred revenue) | 38,132 | 44,202 | ||||
Deferred revenue (including current portion) | 439,212 | 132,303 | ||||
Total liabilities | 518,336 | 220,721 | ||||
Total stockholders’ equity | 335,890 | 267,530 |
Consolidated Statement of Operations Data(in thousands, except share and per share data)
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||||||
Collaboration revenue | $ | 182,413 | $ | 5,904 | $ | 193,091 | $ | 16,245 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||||
Research and development | 43,066 | 43,819 | 136,617 | 112,486 | |||||||||||||||||||||||
General and administrative | 13,018 | 15,834 | 38,105 | 46,175 | |||||||||||||||||||||||
Total operating expenses | 56,084 | 59,653 | 174,722 | 158,661 | |||||||||||||||||||||||
Income (loss) from operations | 126,329 | (53,749 | ) | 18,369 | (142,416 | ) | |||||||||||||||||||||
Other income, net | 268 | 1,045 | 910 | 4,367 | |||||||||||||||||||||||
Net income (loss) | $ | 126,597 | $ | (52,704 | ) | $ | 19,279 | $ | (138,049 | ) | |||||||||||||||||
Net income (loss) per share:Net income (loss) per share, basic | $ | 1.56 | $ | (0.67 | ) | $ | 0.24 | $ | (1.78 | ) | |||||||||||||||||
Net income (loss) per share, diluted | $ | 1.49 | $ | (0.67 | ) | $ | 0.23 | $ | (1.78 | ) | |||||||||||||||||
Weighted-average shares used in calculating:Basic net income (loss) per share | 80,964,701 | 78,771,930 | 80,048,758 | 77,340,896 | |||||||||||||||||||||||
Diluted net income (loss) per share | 85,232,690 | 78,771,930 | 82,871,254 | 77,340,896 |
Alector ContactsMichelle CorralVP, Communications and Investor Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Laura Perry/Eric KasperArgot Partners212.600.1902alector@argotpartners.com
1 Year Alector Chart |
1 Month Alector Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions